Critical Review: Positron (OTCMKTS:POSC) versus Medtronic (NYSE:MDT)

Positron (OTCMKTS:POSC) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Institutional & Insider Ownership

79.6% of Medtronic shares are held by institutional investors. 17.2% of Positron shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Positron and Medtronic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Positron N/A N/A N/A
Medtronic 12.29% 13.85% 7.49%

Risk and Volatility

Positron has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Positron and Medtronic, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Positron 0 0 0 0 N/A
Medtronic 0 5 16 1 2.82

Medtronic has a consensus price target of $144.24, suggesting a potential upside of 10.94%. Given Medtronic’s higher probable upside, analysts clearly believe Medtronic is more favorable than Positron.

Valuation and Earnings

This table compares Positron and Medtronic’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Positron N/A N/A N/A N/A N/A
Medtronic $30.12 billion 5.80 $3.61 billion N/A N/A

Medtronic has higher revenue and earnings than Positron.


Medtronic beats Positron on 9 of the 10 factors compared between the two stocks.

Positron Company Profile

Positron Corp. operates as a nuclear medicine healthcare company specializing in the field of cardiac positron emission tomography imaging. The firm operates through the following segments: Medical Equipment and Radiopharmaceuticals. It provides an economical, end-to-end solution for PET myocardial perfusion imaging through complementary product integration of PET imaging systems, radiopharmaceuticals and radioisotopes. The company was founded by Roman Oliynyk on December 20, 1983 and is headquartered in Niagara Falls, NY.

Medtronic Company Profile

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consists of products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Minimally Invasive Technologies Group segment focuses on respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, and obesity diseases. The Restorative Therapies Group segment comprises of neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The Diabetes Group segment offers insulin pumps, coninuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with's FREE daily email newsletter.